Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.37 |
| ▸ | PDE2A | O00408 | 8/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22748808 | 0.96 | PKM (0.43) | PKMKCNMA1PDE2APDE10APDE7A | |
| SCHEMBL29588139 | 0.96 | PKM (0.43) | PKMKCNMA1PDE2APDE10APDE7A | |
| SCHEMBL29475370 | 0.93 | PKM (0.41) | PKMKCNMA1PDE2APDE10APDE7A | |
| SCHEMBL21073734 | 0.79 | DGAT1 (0.51) | KCNMA1MAPTKDM4EMAPK1HTT | |
| SCHEMBL26185908 | 0.78 | PKM (0.39) | PKMKCNMA1PDE2APDE10ACYP11B2 | |
| SCHEMBL19848305 | 0.73 | KCNMA1 (0.49) | PKMKCNMA1PDE2APDE10AMAPT | |
| SCHEMBL16858668 | 0.73 | PKM (0.41) | PKMKCNMA1PDE2APDE10AGRM2 | |
| SCHEMBL3893181 | 0.73 | DGAT1 (0.57) | KCNMA1MAPTKDM4EMAPK1HTT | |
| SCHEMBL21904738 | 0.71 | DGAT1 (0.51) | KCNMA1MAPTKDM4ELMNAMAPK1 | |
| SCHEMBL1971917 | 0.71 | DGAT1 (0.51) | KCNMA1MAPTKDM4ELMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| US-11975091-B2 | Composition for enhancing protein strength | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2024-05-07 | — | — | US | disclosed |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| EP-4200309-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | ATEA Pharmaceuticals, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| CN-115884977-A | Stereoselective preparation of selected purine phosphoramidates | 阿堤亚制药公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20220233673-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2022-07-28 | — | — | US | disclosed |
| EP-3980057-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | Institut Curie (FR) | 2022-04-13 | — | — | EP | disclosed |
| WO-2022040473-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | PKM 4689/4885KCNMA1 1251/4885PDE2A 4389/4885 |
| US-11975091-B2 | Composition for enhancing protein strength | CUTA, S100A4, S100A8 | PKM 3958/4885KCNMA1 1775/4885PDE2A 4132/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | PKM 4207/4885KCNMA1 970/4885PDE2A 4201/4885 |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | NUDT1, PNP, ATIC | PKM 2510/4885KCNMA1 2597/4885PDE2A 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.